Chat
Medicine · MapleScholar Plus

The Trojan Horse Antibody: How a 1977 Discovery Explained Deadly Dengue Infections

Antibodies are engineered by the immune system to neutralize and destroy invading viruses; weak pre-existing dengue antibodies paradoxically act like a Trojan horse, helping the virus enter and destroy immune cells from the inside. Discovered in 1977 by Scott Halstead after years of medical skepticism, Antibody-Dependent Enhancement explained why secondary dengue infections turn deadly and is the central safety principle guiding global viral vaccine engineering.

Author
SB Halstead et al.
Published
1977
Journal
The Journal of Experimental Medicine
Last updated
September 2026
The Trojan Horse Antibody: How a 1977 Discovery Explained Deadly Dengue Infections

In tropical medicine, doctors were terrified by a medical paradox: when children were infected with Dengue fever a second time by a different strain, they did not have mild immunity—instead, their blood pressure collapsed into lethal Dengue Hemorrhagic Shock.

Infectious disease pioneer Scott Halstead discovered the Trojan horse mechanism: Antibody-Dependent Enhancement (ADE). Weak antibodies left over from the first infection bind to the new virus but fail to kill it—instead, the antibody acts like a VIP backstage pass, escorting the live virus straight into white blood cells where it multiplies millions of times faster.

Halstead’s discovery reshaped virology and vaccine safety. By explaining severe secondary dengue mortality, by preventing flawed viral vaccines (like Dengvaxia) from endangering seronegative children, and by guiding coronavirus vaccine safety, ADE immunology protects global health.

Reference

Halstead, S., & O’Rourke, E. (1977). Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody. The Journal of Experimental Medicine, 146(1), 201–217.

Title

Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody

Abstract

Cultured mononuclear peripheral blood leukocytes (PBL) from nonimmune human beings and monkeys are nonpermissive to dengue 2 virus (D2V) infection at multiplicities of infection of 0.001-0.1, but become permissive when non-neutralizing dengue antibody is added to medium. D2V infection occurred in PBL prepared from anti-coagulated but not from defibrinated plasma. Infection enhancement was produced by multiple lots of heterotypic anti-dengue raised in several mammalian species. Homotypic anti-dengue neutralized D2V at high concentrations but enhanced at low concentrations; enhancement end point in one serum was 1:320,000. The infection-enhancing factor was a noncytophilic antibody of the IgG class. D2V infection occurred in the absence of heat-labile complement components but did not occur when complexes were prepared with anti- dengue F(ab)(2). Treatment of PBL with several proteases increased permissiveness to D2V infection by immune complexes but not by virus alone. Two rhesus monkey serums collected 14 days after D2V infection contained an IgG antibody with high-titered enhancing activity but with no hemagglutination-inhibition or neutralizing activity. Virus-antibody complexes are irreversibly attached to PBL within 15 min and completely internalized in 60 min. There was considerable variation in cellular infection in different experiments, however, maximum virus yields usually exceeded 1,000 plaque-forming units per 1 x 10(6) PBL occurring between 2 and 4 days in culture. In vitro antibody-dependent infection of PBL provides a possible model for study of pathogenetic mechanisms in infants with dengue shock syndrome who passively acquire maternal anti-dengue IgG.

Cited 814 times · View on doi.org

Continue

Continue Exploring

Ask this paper your own questions, or keep browsing the verified research catalogue.